The rise of the generic drug market and its implications for dermatology

Journal of Dermatological Treatment

Volumn 16, Issue 5-6, 2005, Pages 295-298

  Bhosle, Monali ^a   Balkrishnan, Rajesh ^a,b   Dewan, Tina ^b   Yelverton, Christopher B ^a   Feldman, Steven R ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Generic drug substitution; Generic drugs; Topical drugs

Indexed keywords

ADAPALENE; AMLODIPINE BESYLATE; AMMONIUM LACTATE; AMOXICILLIN; ATENOLOL; ATORVASTATIN; AZITHROMYCIN; BENZOYL PEROXIDE; CEFACLOR; CLINDAMYCIN PHOSPHATE; CLOBETASOL; CLOBETASOL PROPIONATE; CONJUGATED ESTROGEN; DESOXIMETASONE; ERYTHROMYCIN; FLUOCINONIDE; FLUTICASONE PROPIONATE; FUROSEMIDE; GENERIC DRUG; HYDROCHLOROTHIAZIDE; HYDROCODONE; IBUPROFEN; ISOTRETINOIN; LEVOTHYROXINE SODIUM; LISINOPRIL; NAPROXEN; PREDNISONE; RANITIDINE; RETINOIC ACID; TACROLIMUS; TERFENADINE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ARTICLE; DATA ANALYSIS; DATA BASE; DERMATOLOGY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MARKETING; ECONOMIC ASPECT; MEDICAL LITERATURE; PRESCRIPTION; PRIORITY JOURNAL; SOCIAL ASPECT; UNITED STATES;

DERMATOLOGIC AGENTS; DERMATOLOGY; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 31644450337     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630500420530     Document Type: Article

References (19)

1. Ascione FJ, Kirking DM, Gaither CA, Welage LS. Historical overview of generic medication policy. J Am Pharm Assoc. 2001;41:567-77.
2. NDCHealth, PharmaTrends 2002 Year in Review, NDC Corporation. Available at http://ndchealthcom/epharma/yir/ pharmatrends2002 pdf [Accessed 11 May 2005].
3. Steger JW, Wolverton SE, Greenberg RD, Ling MR, Resnick SD, James WD. Dermatologic drug formulary: an American Academy of Dermatology white paper. J Am Acad Dermatol. 1996;34:99-109.
4. Shah VP. Progress in methodologies for evaluating bioequivalence of topical formulations. Am J Clin Dermatol. 2001;2:275-80.
5. Ling MR. The message in the medium: how and why to choose a vehicle. Fitzpatrick's J Clin Dermatol. 1995;3:13-19.
6. Castanedo-Cazares JP, Quistian-Galvan J, Torres-Alvarez B, Torres-Ruvalcaba A, Moncada B. Antiinflammatory effect of a topical corticosteroid: known brand versus generic drug. Gac Med Mex. 2001;137:311-14.
7. Cohen JB, Bergstresser PR. Response of Behcet's syndrome to brand-name but not generic tetracycline. Clin Exp Dermatol. 1997;22:159-60.
8. Burova K, Bansal D. Skin eruption to generic prednisolone. Br J Dermatol. 1999;141:597-8.
9. Louet S. Lessons from Eprex for biogeneric firms. Nat Biotechnol. 2003;21:956-7.
10. National Health Center for Health Statistics, Centers for Disease Control. Available at http://www.edc.gov/nchs/about/ major/ahed/namesdes/html [Accessed 11 May 2005].
11. Red Book 2004, 108th edn, Montvale, NJ: Medical Economics Co., 2004.
12. CDER New and Generic Drug Approvals 1998-2004, Center for Drug Evaluation and Research, FDA. Available at: URL: http://www.fda.gov/cder/approval/ [Accessed 11 May 2005].
13. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Executive Summary, July 1998. Available at http://www.cbo.gov/ showdoc.cfm?index=655&sequence=0&from=1 [Accessed 11 May 2005].
14. Skernivitz TP. Accutane goes generic. Dermatology Times 2002.
15. Walgreen's Pharmacy On-Line. Available from: URL: http://www.walgreens. com/library/finddrug/druginfosearch.jhtml [Accessed 10 May 2005].
16. Smith ES, Fleischer AB Jr, Feldman SR. Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994. J Am Acad Dermatol. 1998;39:43-7.
17. Goodwin FK. Impact of formularies on clinical innovation. J Clin Psychiatry. 2003;64(Suppl 17):11-14.
18. Kirking DM, Ascione FJ, Gaither CA, Welage LS. Economics and structure of the generic pharmaceutical industry. J Am Pharm Assoc. 2001;41:578-84.
19. Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res. 2003;38:1051-63.